Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35% Trials ...
PDS01ADC is a tumor-targeted IL-12 immunocytokine designed to activate the immune system directly within the tumor ...
These advances, still under investigation, hold the promise of revolutionizing healthcare for future colorectal cancer ...
Stocktwits on MSN
PDSB stock hits 37-week high — here’s the latest on its therapy to treat metastatic colorectal cancer
The trial focused on patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer with liver metastases ・The treatment delivered an ORR of nearly 78%, compared to 35% ...
PDS Biotech’s stock has jumped nearly 25% after its tumour-targeting fused antibody drug conjugate (ADC) elicited a 78% ...
Detailed price information for Pds Biotechnology Corp (PDSB-Q) from The Globe and Mail including charting and trades.
Preliminary results of fruquintinib in combination with FOLFIRI as second-line treatment for RAS-mutant metastatic colorectal cancer: A prospective, single-center phase 2 study. Efficacy and safety of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results